Market Overview

Gilead Sciences Rises After Q2 Report (GILD)

Share:
Gilead Sciences Rises After Q2 Report GILD
Related GILD
Jim Cramer Advises Viewers On Schlumberger, Gilead Sciences And Disney
The Next Sector Rotation Will Be To Biotechs
Regeneron Up As Eylea Beats Views; Merck Down As Lead Drugs Slip (Investor's Business Daily)

Biotechnology giant Gilead Sciences (NASDAQ: GILD which has a market-cap approaching $100 billion, released its fiscal second quarter earnings results after the closing bell on Thursday.

The company reported adjusted earnings per share that was in-line with estimates and revenue that exceeded Wall Street expectations. In late trade, shares were last up almost 6 percent to $64.26.

Related:Find all of Thursday's stock movers in Benzinga's daily Market Wrap

Q2 Financial Results

Gilead reported net income of $772.6 million or $0.46 per share, compared to $711.6 million or $0.46 per share, in last year's second quarter.

On an adjusted basis, net income was $839.7 million or $0.50 per share, versus $767.3 million or $0.49 per share, in the year ago period. This was in-line with analysts' estimates.

Total revenue in the quarter was up 15 percent to $2.77 billion from $2.41 billion a year ago. This compared to analysts' consensus revenue estimates of $2.66 billion. Product sales rose 14 percent in the quarter to $2.66 billion from $2.32 billion last year.

Posted-In: Earnings News After-Hours Center Movers Best of Benzinga

 

Related Articles (GILD)

View Comments and Join the Discussion!